Tucuvi

About Tucuvi

Tucuvi is a Spanish healthtech company building autonomous clinical voice AI. Its agent, LOLA, places and receives patient phone calls, executes more than 50 clinical and care-coordination workflows — post-surgical follow-ups, chronic-care monitoring, medication management — and escalates to human care teams when a patient needs attention. Hospitals report up to 80% automation of nursing follow-up workflows and patient engagement above 90%, across more than 300,000 calls. The company positions regulatory rigour as a differentiator. Tucuvi reports that both its voice agent and its patient-management platform (Tucuvi Health Manager) hold European regulatory approval as Class IIb Software as a Medical Device — a higher medical-device risk class than most clinical AI tools — operated under a quality management system based on ISO 13485. It is ISO/IEC 27001 certified and SOC 2 compliant, complies with GDPR and HIPAA, and states it is aligning with the EU AI Act and BS 30440 for clinical AI assurance. Tucuvi is incorporated as Tucuvi Care S.L. in Madrid (founded 2019 by Marcos Rubio and María González Manso) with no US parent, placing it within EU jurisdiction. Its AI agents are trained on a proprietary dataset of manually labelled medical phone conversations rather than on live customer patient data, though the company does not publish an explicit no-training-on-customer-data guarantee or detailed data-residency commitments on its public pages, so enterprise buyers should confirm hosting region and retention terms via its Trust Center and DPA. In January 2026 Tucuvi raised a $20M (€17M) Series A led by Cathay Innovation and Kfund/Leadwind, with Frontline Ventures, Seaya Ventures and Shilling participating, and is deployed across 60+ health systems with roughly 50 employees. For EU health systems that want autonomous patient outreach delivered as a certified medical device, Tucuvi is a strong fit; sovereignty-focused buyers should verify EU data-hosting specifics directly given the limited public disclosure.